Due to health issues, this site is no longer maintained and will be shut down shortly.

DICE DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is S011806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4▀7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aV▀1/aV▀6 integrin for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

$27.58  +0.37 (1.36%)
As of 03/27/2023 14:09:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/15/2021
Outstanding shares:  47,711,123
Average volume:  488,208
Market cap:   $1,278,658,096
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BNRPLC7
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy